ClinicalTrials.gg
CompletedNCT01203111CHANGINGUpdated Aug 30, 2012

Intensive Insulin Glulisine Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Basal Insulin and Oral Glucose-lowering Drugs

A Phase 4 interventional study of INSULIN GLARGINE and INSULIN GLULISINE in Diabetes Mellitus, Type 2, sponsored by Sanofi. Completed at 10 sites in 10 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2012-08-30.

Sponsored by Sanofi · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
207
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 26 studies testing insulin glulisine in Diabetes Mellitus, Type 2 — none open to participants now, none under way, none of them phase 3. insulin glulisine · Diabetes Mellitus, Type 2.

Enrollment
16th of 25
207 · median 281
Started
2010
with 2 others
Phase 4
14 of 26
none open now
Registered
19th of 26
by date
Lead sponsor
19 of 26
Sanofi

Among the 26 studies testing insulin glulisine in Diabetes Mellitus, Type 2, this one is the 16th largest by enrollment of the 25 interventional ones that give a count, is one of 3 that started in 2010, is one of 14 in phase 4, and was the 19th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

None of the 26 studies testing insulin glulisine in Diabetes Mellitus, Type 2 is open now. The open studies under Diabetes Mellitus, Type 2, anywhere →

About insulin glulisine

insulin glulisine: first FDA approval 2004 (APIDRA SOLOSTAR), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 26 studies testing insulin glulisine in Diabetes Mellitus, Type 2 as a file.
02

Study summary

Primary Objective:

To evaluate the efficacy of an intensive insulin regimen with insulin glargine and insulin glulisine in terms of change in Hemoglobin A1c (HbA1c) level from week 12 (visit 7) to week 24 (visit 10).

Secondary Objectives:

  1. Percentage of patients with HbA1c \< 7% at week 24.
  2. Percentage of patients with HbA1c \< 7% and no symptomatic nocturnal hypoglycemia event at week 24.
  3. Fasting Plasma Glucose (FPG) and 7-point Self Monitoring of Blood Glucose (SMBG) at week 0, week 12 and week 24.
  4. Doses of insulin glargine and insulin glulisine: the daily dose (U) and the daily dose / kg (U/kg) will be calculated at week 24.
  5. Systolic and diastolic blood pressure, heart rate, weight change will be measured at week 0, week 12 and week 24.
  6. Number of patients suffering hypoglycemias (asymptomatic, symptomatic, nocturnal symptomatic, severe and nocturnal severe) will be evaluated during the treatment period. 7-Adverse events.
Read the detailed description

The study is divided in 3 periods:

  1. a 2-week run-in period,
  2. a 12-week treatment period 1
  3. a 12-week treatment period 2 study treatment duration per patient: 24 weeks study duration per patient: 26 weeks
03

Conditions studied

  • Diabetes Mellitus, Type 2
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • in the run-in period:

    1. Uncontrolled Type 2 diabetes mellitus defined as level between 7,5% and 10% assessed over the past 6 months
    2. Male or female patients from 18-75 years old inclusive
    3. (BMI) between 25 and 40 kg/m2
    4. Currently treated with a basal insulin (NPH, insulin zinc or insulin detemir), plus at least 1g metformin daily, and other Oral Glucose Lowering Drug (OGLD) if any for at least 3 months
    5. Signed obtained prior to any study procedures
  • in the treatment period:

    1. HbA1c level between 7,5% and 10% assessed between week -2 and week 0
    2. Serum creatinine \<= 135 µmol/L in men and \<= 110 µmol/L in women
    3. (ALT) and/or Aspartate aminotransferase (AST) \<= 3 times the
    4. Negative pregnancy test for women of

Exclusion criteria

Exclusion criteria:

  1. Type 1 diabetes mellitus
  2. Active proliferative diabetic retinopathy, defined as the application of photocoagulation or surgery performed within 6 months before study entry or any other unstable (rapidly progressing) retinopathy that may require photocoagulation or surgery during the study (confirmed by an optic fundus performed over the past 2 years)
  3. cardiovascular, hepatic, neurological, endocrine, or other major disease making implementation of the protocol or interpretation of the study results difficult
  4. History of impaired hepatic function defined as (ALT) and/or Aspartate aminotransferase (AST) greater than three times the
  5. History of impaired renal function defined as serum creatinine >135 µmol/l in men and > 110 µmol/l in women
  6. History of drug or alcohol abuse
  7. Type 2 Diabetes Mellitus (T2DM) patients treated exclusively with OGLDs
  8. T2DM patients treated with an insulin other than basal insulin (Premix, rapid insulin, fast-acting insulin analogue)
  9. Previous treatment with insulin glulisine
  10. Concomitant treatment with thiazolidinediones, exenatide or pramlintide
  11. Treatment with systemic within 3 months prior to study entry
  12. Treatment with any product within 2 months prior to study entry
  13. History of to the study drugs or to drugs with a similar chemical structure
  14. Presence of mental condition that, in the opinion of the investigator, indicates that participation in the study is not in the best interest of the patient
  15. Presence of geographic or social conditions that would restrict or limit the patient participation for the duration of the study
  16. Pregnant or breast feeding women
  17. Women of not protected by effective method of birth control

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
207 participants (actual)

Study arms

  • Experimental
    Intensive insulin regimen

    Treatment Period 1: Insulin glargine + metformin + other OGLDs, if any Treatment period 2: + insulin glulisine if HbA1c ≥7% at week 12 (end of treatment period 1)

    Drug: INSULIN GLARGINE · Drug: INSULIN GLULISINE

  • Experimental
    insulin regimen

    Treatment Period 1: Insulin glargine + metformin + other OGLDs, if any Treatment period 2: no change, if HbA1c \<7% at week 12 (end of treatment period 1)

    Drug: INSULIN GLARGINE

Interventions

  • Pharmaceutical form: solution for injection Route of administration: sub-cutaneous Dose regimen: once a day in the evening at bedtime

    Also known as: Lantus SoloStar

  • Pharmaceutical form: solution for injection Route of administration: sub-cutaneous Dose regimen: once a day, 0 to 15 minutes before the main meal

    Also known as: Apidra SoloStar

06

What researchers measure

Primary outcomes

  1. Change in HbA1c level for patients with addition of glulisine at week 12

    Time frame: between week 12 and week 24 (end of treatment period)

Secondary outcomes

  1. Percentage of patients with HbA1c level < 7%

    Time frame: at week 24 (end of treatment period)

  2. Percentage of patients with HbA1c level < 7% and no symptomatic nocturnal hypoglycemia event

    Time frame: at week 24 (end of treatment period)

  3. Fasting Plasma Glucose

    Time frame: at week 0, week 12 and week 24

  4. 7-point Self Monitoring of Blood Glucose

    Time frame: at week 0, week 12 and week 24

  5. Daily dose of insulin glargine

    Time frame: at week 24 (end of treatment period)

  6. Daily dose of insulin glulisine

    Time frame: at week 24 (end of treatment period)

  7. Systolic / diastolic blood pressure, heart rate, weight change

    Time frame: from week 0 (baseline) to week 24 (end of treatment period)

  8. Hypoglycemia (asymptomatic, symptomatic, nocturnal symptomatic, severe and nocturnal severe)

    Time frame: from week 0 (from baseline) to week 24 (end of treatment)

07

Study locations

10 sites
  • Administrative office
    Algiers, Algeria
  • Administrative office
    Sao Paulo, Brazil
  • Administrative office
    Natanya, Israel
  • Administrative office
    Beirut, Lebanon
  • Administrative office
    Col. Coyoacan, Mexico
  • Administrative office
    Casablanca, Morocco
  • Administrative office
    Lima, Peru
  • Administrative office
    Jeddah, Saudi Arabia
  • Administrative office
    Dubaï, United Arab Emirates
  • Administrative office
    Caracas, Venezuela
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2010, a primary completion of Jul 2012 and a completion of Jul 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 14, 2010
First posted
Sep 16, 2010
Start
Dec 2010
Primary completionActual
Jul 2012
CompletionActual
Jul 2012
Last update
Aug 30, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 30, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01203111
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Sep 16, 2010
Start date
Dec 2010
Primary completion
Jul 2012
Completion
Jul 2012
Last update
Aug 30, 2012

Study contacts

Clinical Sciences & Operations
study director · Sanofi
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Insulin glulisine

Start the discussion